Refine Results
  1. "European Urology"
Formats
  1. Journal Article (424)
  2. Correspondence (11)
  3. Editorial (10)
  4. Conference Paper (8)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Review (1)
Groups
  1. Surgery (261)
  2. Genitourinary Disease Management Team (190)
  3. Population Sciences Research Program (123)
  4. Epidemiology and Biostatistics (114)
  5. Health Outcomes Research Group (80)
  6. Solid Tumor Oncology Division (77)

More Groups

People
  1. Andrew Vickers (78)
  2. James Eastham (50)
  3. Harry Herr (44)
  4. Abdelkrim Touijer (42)
  5. Bernard Bochner (38)
  6. Peter Scardino (35)

More People

Years
  1. 2021 (11)
  2. 2020 (30)
  3. 2019 (27)
  4. 2018 (26)
  5. 2017 (25)
  6. 2016 (24)

More Years

Publications
  1. European Urology (458)
Publishers
  1. Elsevier Science, Inc. (458)

Results (458)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The clinicopathologic and molecular landscape of clear cell papillary renal cell carcinoma: Implications in diagnosis and management
    Journal Article

    Weng, S.; DiNatale, R. G.; Silagy, A.; Mano, R.; Attalla, K.; Kashani, M.; Weiss, K.; Benfante, N. E.; Winer, A. G.; Coleman, J. A.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: A randomized phase 2 clinical trial
    Journal Article

    Powles, T.; Atkins, M. B.; Escudier, B.; Motzer, R. J.; Rini, B. I.; Fong, L.; Joseph, R. W.; Pal, S. K.; Sznol, M.; Hainsworth, J.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: A prespecified subgroup analysis of the IMmotion151 clinical trial
    Journal Article

    Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R.; Bracarda, S.; Bedke, J.; De Giorgi, U.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: Reconstructing prespecified endpoints for cohort B from the phase 3 PROfound trial of olaparib
    Research Letter

    Stopsack, K. H.
    European Urology (2021)

    Fulltext@MSK | Save
  • Statins and prostate cancer: Bias, precision medicine, or population health?
    Editorial

    Stopsack, K. H.
    European Urology (2021)

    Fulltext@MSK | Save
  • Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's letter to the editor re: Konrad H. Stopsack. Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: Reconstructing prespecified endpoints for cohort B from the phase 3 PROfound trial of olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024
    Correspondence

    Stopsack, K. H.
    European Urology (2021)

    Fulltext@MSK | Save
  • A systematic review of the evidence for the Decipher genomic classifier in prostate cancer
    Review

    Jairath, N. K.; Dal Pra, A.; Vince, R. Jr; Dess, R. T.; Jackson, W. C.; Tosoian, J. J.; McBride, S. M.; Zhao, S. G.; Berlin, A.; Mahal, B. A.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: Final overall survival analysis of the phase 3 PROTECT trial
    Journal Article

    Motzer, R. J.; Russo, P.; Haas, N.; Doehn, C.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Lim, H. Y.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Problems with numbers in decision aids for prostate-specific antigen screening: A critical review
    Editorial

    Carlsson, S. V.; Vickers, A. J.; Gonsky, J. P.; Hay, J. L.; Hu, J. C.
    European Urology (2021)

    Fulltext@MSK | Save
  • Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016
    Correspondence

    Iyer, G.; Bochner, B. H.; Van Allen, E. M.; Solit, D. B.; Rosenberg, J. E.
    European Urology (2021)

    Fulltext@MSK | Save